In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients

Anna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad · 2025

Read In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients by Anna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12660821.txt.

Description

Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates vary widely between subgroups, with an average overall survival of 70%. Recurrent medulloblastoma is highly aggressive, treatment-resistant, and usually fatal. In addition, current treatments are highly toxic to the developing brain and surviving patients suffer from lifelong side effects. Therefore, novel therapeutic options are urgently needed.

Catalog record

CREATORAnna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE42 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12660821

Browse the full library · About the Tower of Babel